Table 1.
Characterization of the 367 participants at each time point
| 0 months | 6 months | 12 months | |
|---|---|---|---|
| n | 367 | 367 | 367 |
| Female (n, %) | 287 (78.2%) | 287 (78.2%) | 287 (78.2%) |
| Male (n, %) | 80 (21.8%) | 80 (21.8%) | 80 (21.8%) |
| Age (years), median (IQR) | 50 (40; 56) | 50 (40; 57) | 51 (41; 57) |
| BMI (ratio), median (IQR) | 23.7 (21.5; 27.3) | 24.0 (22.0; 27.0) | 23.7 (21.8; 27.0) |
| Comorbidities (n, %) | 162 (44.1%) | 162 (44.1%) | 162 (44.1%) |
| HCWs (n, %) | 93 (25.3%) | 93 (25.3%) | 93 (25.3%) |
| New infections (n, %) | 34 (9.3%) | 40 (10.9%) | 18 (4.9%) |
| Total number of infected (n, %) | 34 (9.3%) | 74 (20.2%) | 92 (25.0%) |
| Time between infection and sampling (days), median (IQR) | 68.5 (33.3; 164.5) | 258.5 (226.5; 374.3) | 387.5 (263.8; 479.8) |
| Vaccinated (n, %) | 0 | 245 (66.8%) | 341 (92.9%) |
| Unvaccinated (n, %) | 367 (100%) | 122 (33.2%) | 26 (7.1%) |
| Number of vaccine doses (n, %) | 0 (367, 100%) | 0 (122, 33.2%) | 0 (26, 7.1%) |
| 1 (100, 27.2%) | 1 (60, 16.3%) | ||
| 2 (145, 39.5%) | 2 (244, 66.5%) | ||
| 3 (0) | 3 (37, 10.1%) | ||
| Vaccinated and naive to infection (n, %) | – | 208 (56.7%) | 259 (70.7%) |
| Vaccinated and infected (n, %) | – | 37 (10.0%) | 82 (22.3%) |
| Unvaccinated and infected (n, %) | 34 (9.3%) | 38 (10.4%) | 10 (2.7%) |
| Unvaccinated and naive to infection (n, %) | 333 (90.7%) | 84 (22.9%) | 16 (4.4%) |
| Time between vaccination and sampling (days), median (IQR) | – | 39 (21; 75) | 188 (140; 230) |
| Anti-SP IgG (BAU/mL), median (IQR) | 59.5 (33.75; 165.5) | 278.5 (94; 918.5) | 248 (108.8; 734) |
| Anti-N IgG positivity (n, %) | – | 30 (40.5% of infected) | 26 (28.3% of infected) |
| Neutralization of Wuhan variant, median (IQR) | 2.6 (1.4; 4.3) | 7.4 (2.4; 16.6) | 6.4 (2.5; 14.0) |
| Neutralization of Alpha variant, median (IQR) | 2.2 (1.2; 3.5) | 6.0 (1.9; 14.9) | 5.1 (2.1; 12.8) |
| Neutralization of Delta variant, median (IQR) | 2.6 (1.1; 3.9) | 5.9 (1.9; 14.5) | 5.5 (2.2; 13.5) |
| SARS-CoV-2 specific T cell response (IU/mL), median (IQR) | – | – | 0.41 (0.22; 0.9) |
N number, IQR interquartile range, HCW health care workers, Anti-SP anti-Spike, IgG immunoglobulin G, Anti-N anti-nucleocapsid